Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease - PubMed

Affiliations

• PMID: 11988536
• DOI: 10.1126/science.1072613

Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease

Anthone W Dunah et al. Science. 2002.

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disease caused by expansion of a polyglutamine tract in the huntingtin protein. Transcriptional dysregulation has been implicated in HD pathogenesis. Here, we report that huntingtin interacts with the transcriptional activator Sp1 and coactivator TAFII130. Coexpression of Sp1 and TAFII130 in cultured striatal cells from wild-type and HD transgenic mice reverses the transcriptional inhibition of the dopamine D2 receptor gene caused by mutant huntingtin, as well as protects neurons from huntingtin-induced cellular toxicity. Furthermore, soluble mutant huntingtin inhibits Sp1 binding to DNA in postmortem brain tissues of both presymptomatic and affected HD patients. Understanding these early molecular events in HD may provide an opportunity to interfere with the effects of mutant huntingtin before the development of disease symptoms.

Comment in

• Neurodegeneration. A glutamine-rich trail leads to transcription factors.

  Freiman RN, Tjian R. Freiman RN, et al. Science. 2002 Jun 21;296(5576):2149-50. doi: 10.1126/science.1073845. Science. 2002. PMID: 12077389 No abstract available.

Similar articles

• Neurodegeneration. A glutamine-rich trail leads to transcription factors.

  Freiman RN, Tjian R. Freiman RN, et al. Science. 2002 Jun 21;296(5576):2149-50. doi: 10.1126/science.1073845. Science. 2002. PMID: 12077389 No abstract available.

• Interaction of Huntington disease protein with transcriptional activator Sp1.

  Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ. Li SH, et al. Mol Cell Biol. 2002 Mar;22(5):1277-87. doi: 10.1128/MCB.22.5.1277-1287.2002. Mol Cell Biol. 2002. PMID: 11839795 Free PMC article.

• Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease.

  Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, MacDonald ME, Cha JH. Chen-Plotkin AS, et al. Neurobiol Dis. 2006 May;22(2):233-41. doi: 10.1016/j.nbd.2005.11.001. Epub 2006 Jan 24. Neurobiol Dis. 2006. PMID: 16442295

• Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.

  Truant R, Atwal RS, Burtnik A. Truant R, et al. Prog Neurobiol. 2007 Nov;83(4):211-27. doi: 10.1016/j.pneurobio.2006.11.004. Epub 2007 Jan 22. Prog Neurobiol. 2007. PMID: 17240517 Review.

• Molecular aspects of Huntington's disease.

  Walling HW, Baldassare JJ, Westfall TC. Walling HW, et al. J Neurosci Res. 1998 Nov 1;54(3):301-8. doi: 10.1002/(SICI)1097-4547(19981101)54:3<301::AID-JNR1>3.0.CO;2-W. J Neurosci Res. 1998. PMID: 9819135 Review.

Cited by

• Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis.

  Miller MS, Rialdi A, Ho JS, Tilove M, Martinez-Gil L, Moshkina NP, Peralta Z, Noel J, Melegari C, Maestre AM, Mitsopoulos P, Madrenas J, Heinz S, Benner C, Young JA, Feagins AR, Basler CF, Fernandez-Sesma A, Becherel OJ, Lavin MF, van Bakel H, Marazzi I. Miller MS, et al. Nat Immunol. 2015 May;16(5):485-94. doi: 10.1038/ni.3132. Epub 2015 Mar 30. Nat Immunol. 2015. PMID: 25822250 Free PMC article.

• The promise and perils of HDAC inhibitors in neurodegeneration.

  Didonna A, Opal P. Didonna A, et al. Ann Clin Transl Neurol. 2015 Jan;2(1):79-101. doi: 10.1002/acn3.147. Epub 2014 Dec 3. Ann Clin Transl Neurol. 2015. PMID: 25642438 Free PMC article. Review.

• Histone methylation in the nervous system: functions and dysfunctions.

  Pattaroni C, Jacob C. Pattaroni C, et al. Mol Neurobiol. 2013 Apr;47(2):740-56. doi: 10.1007/s12035-012-8376-4. Epub 2012 Nov 17. Mol Neurobiol. 2013. PMID: 23161382 Review.

• Elevated SLC7A2 expression is associated with an abnormal neuroinflammatory response and nitrosative stress in Huntington's disease.

  Gaudet ID, Xu H, Gordon E, Cannestro GA, Lu ML, Wei J. Gaudet ID, et al. J Neuroinflammation. 2024 Feb 28;21(1):59. doi: 10.1186/s12974-024-03038-2. J Neuroinflammation. 2024. PMID: 38419038 Free PMC article.

• Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.

  Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. Kim J, et al. Hum Mol Genet. 2010 Oct 15;19(20):3919-35. doi: 10.1093/hmg/ddq306. Epub 2010 Jul 21. Hum Mol Genet. 2010. PMID: 20660112 Free PMC article.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • H1 Connect
  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • BioCyc